Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024
Alan H. Bryce MD, Neeraj Agarwal MD, Himisha Beltran MD, Maha H. Hussain MD, Oliver Sartor MD, Neal Shore MD, Emmanuel S. Antonarakis MD, Andrew J. Armstrong MD, MSc, Jeremie Calais MD, PhD, Michael A. Carducci MD, Tanya Barauskas Dorff MD, Jason A. Efstathiou MD, DPhil, Martin Gleave MD, Leonard G. Gomella MD, Celestia Higano MD, Thomas A. Hope MD, Andrei Iagaru MD, Alicia K. Morgans MD, MPH, David S. Morris MD, Michael J. Morris MD, Daniel P. Petrylak MD, Robert E. Reiter MD, Matthew B. Rettig MD, MBA, Charles J. Ryan MD, Scott B. Sellinger MD, Daniel E. Spratt MD, Sandy Srinivas MD, Scott T. Tagawa MD, MS, Mary-Ellen Taplin MD, Evan Y. Yu MD, Tian Zhang MD, Rana R. McKay MD, Phillip J. Koo MD, E. David Crawford MD
{"title":"Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024","authors":"Alan H. Bryce MD, Neeraj Agarwal MD, Himisha Beltran MD, Maha H. Hussain MD, Oliver Sartor MD, Neal Shore MD, Emmanuel S. Antonarakis MD, Andrew J. Armstrong MD, MSc, Jeremie Calais MD, PhD, Michael A. Carducci MD, Tanya Barauskas Dorff MD, Jason A. Efstathiou MD, DPhil, Martin Gleave MD, Leonard G. Gomella MD, Celestia Higano MD, Thomas A. Hope MD, Andrei Iagaru MD, Alicia K. Morgans MD, MPH, David S. Morris MD, Michael J. Morris MD, Daniel P. Petrylak MD, Robert E. Reiter MD, Matthew B. Rettig MD, MBA, Charles J. Ryan MD, Scott B. Sellinger MD, Daniel E. Spratt MD, Sandy Srinivas MD, Scott T. Tagawa MD, MS, Mary-Ellen Taplin MD, Evan Y. Yu MD, Tian Zhang MD, Rana R. McKay MD, Phillip J. Koo MD, E. David Crawford MD","doi":"10.1002/cncr.35612","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694557/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35612","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence.
期刊介绍：
The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society.
CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
